Methadone-dexmedetomidine-ketamine combination

Phase 3Small molecule

Methadone-dexmedetomidine-ketamine combination is one of 3 small molecule programs targeting Postoperative Pain Control. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postoperative Pain ControlNot yet recruiting

Postoperative Pain ControlPhase 3

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Postoperative Pain Control

#DrugCompanyPhaseTrials

Dinalbuphine Sebacate

LLumosa Therapeutics Co., Ltd.

Phase 3

1 2

Methadone-dexmedetomidine-ketamine combination

UUniversity of Missouri-Columbia

Phase 3

1 3

Spinal Morphine

MMahidol University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalNot yet recruiting

Postoperative Pain Control

NCT07365800

Clinical

Trials by Indication[1]

Postoperative Pain Control1 trial

The MDK Study: Using a Combination of Methadone-dexmedetomidine-ketamine for Postoperative Pain Control in Patients Undergoing Complex Spine Surgeries.

Not yet recruiting·UUniversity of Missouri-Columbia·Phase 4·NCT07365800·248 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Methadone-dexmedetomidine-ketamine combination. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methadone-dexmedetomidine-ketamine combination compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methadone-dexmedetomidine-ketamine combination. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Missouri-Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Missouri-Columbia

Methadone-dexmedetomidine-ketamine combination

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Postoperative Pain Control1 trial

References

Drug Info

Quick Facts

Related News